Enanta Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 145
- Market Cap
- $275.6M
- Introduction
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also con...
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT06601192
- Locations
- πΊπΈ
ICON Early Phase, LLC, San Antonio, Texas, United States
πΊπΈICON, Lenexa, Kansas, United States
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 142
- Registration Number
- NCT06170242
- Locations
- π¬π§
hVIVO Services Limited, London, United Kingdom
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 231
- Registration Number
- NCT05616728
- Locations
- π·π΄
County Emergency Hospital, Cluj-Napoca, Cluj, Romania
πΊπΈD&H National Research Centers, Miami, Florida, United States
πΊπΈUSPA Advance Concept Medical Research Group. LLC, Miami, Florida, United States
Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT05594615
- Locations
- πΊπΈ
ICON, plc., Salt Lake City, Utah, United States
Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05594602
- Locations
- πΊπΈ
ICON, plc., Lenexa, Kansas, United States
A Study of EDP-323 in Healthy Subjects
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 82
- Registration Number
- NCT05587478
- Locations
- πΊπΈ
ICON, plc., Lenexa, Kansas, United States
A Study of EDP-938 in Non-hospitalized Adults with RSV Who Are At High Risk for Complications.
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 180
- Registration Number
- NCT05568706
- Locations
- πΊπΈ
Global Health Institute, Syracuse, New York, United States
πΊπΈLongwood Research, Huntsville, Alabama, United States
πΊπΈVoyage Medical, Tempe, Arizona, United States
A Study of EDP-235 in Healthy Subjects
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT05246878
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 26
- Registration Number
- NCT04971512
- Locations
- π³πΏ
New Zealand Clinical Research Ltd, Auckland, New Zealand
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 8
- Registration Number
- NCT04927793
- Locations
- πΊπΈ
Covance Clinical Research Unit, Madison, Wisconsin, United States